Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial

Recruiting

PHASE2Ages 18+InterventionalTreatment

University of Vermont Medical Center

~103 participants

Updated 2026-02-05 on ClinicalTrials.gov

What's tested:Hybrid Palliative Radiation Therapy

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Incidence of acute gastrointestinal (GI) toxicity

Measured over 4 weeks

Palliative Radiotherapy

Metastatic Cancer (Different Solid Tumour Types)

NCT06778408

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

University of Vermont Medical Center
Burlington, Vermontstudy coordinator listed
Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Nataniel H Lester-Coll, MD

Opens a ready-to-send draft in your own email app — review before sending.

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Has not undergone a hysterectomy or bilateral oophorectomy; or

Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).

Incidence of acute gastrointestinal (GI) toxicity4 weeks
Th incidence of acute gastrointestinal (GI) toxicity (defined as a score of ≥2) at 4 weeks post-treatment initiation will be measured and compared to historical data, using PRO-CTCAE GI scores to determine if HART reduces GI toxicity.